(+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors

JP Sullivan, MW Decker, JD Brioni, D Donnelly-Roberts, DJ Anderson, AW Bannon, CH Kang, P Adams, M Piattoni-Kaplan and MJ Buckley

Phamaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois.

(+/-)-Epibatidine, exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-[2.2.1] heptane, is a novel, potent analgesic agent that acts through nicotinic acetylcholine receptor (nAChR) mechanisms. This study sought to establish whether (+/-)-epibatidine, like (-)-nicotine, also displays a wide diversity of behavioral responses that are known to be elicited by nAChR activation or whether it demonstrates subtype selectivity for its interactions with nAChRs.(+/-)-Epibatidine displaced [3H](-)-cytisine binding to the alpha 4 beta 2 nAChR subtype in rat brain membranes with high affinity (Ki, 43 pM). The compound was approximately 5000-fold less potent (Ki = 230nM) in the displacement of [125I] alpha- bungarotoxin binding from the alpha-bungarotoxin-sensitive nAChR subtype present in rat brain but was a potent inhibitor (Ki, 2.7 nM) of [125I] alpha-bungarotoxin binding to the nAChR subtype in Torpedo electroplax, which is similar to that present in the neuromuscular junction. Functionally, (+/-)-epibatidine enhanced 86Rb+ flux in IMR 32 cells with an EC50 value of 7 nM. It was some 3000-fold more potent than (-)-nicotine (EC50 value, 21,000 nM) and was approximately 150- fold more potent (EC50 value, 0.4 nM) than (-)-nicotine (EC50 value = 60 nM) in increasing [3H]dopamine release from rat striatal slices. Remarkably, (+/-)-epibatidine was 40% to 50% more efficacious than (-)- nicotine in both functional assays. Both functional effects were blocked by the nAChR channel blocker, mecamylamine (100 microM). (+/-)- Epibatidine was 300 to 1000 times more potent than (-)-nicotine in the reduction of body temperature and locomotor activity in mice.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 271, Issue 2, pp. 624-631, 11/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Zwart, A. L. Carbone, M. Moroni, I. Bermudez, A. J. Mogg, E. A. Folly, L. M. Broad, A. C. Williams, D. Zhang, C. Ding, et al. Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant {alpha}4{beta}2 Nicotinic Acetylcholine Receptors Mol. Pharmacol., June 1, 2008; 73(6): 1838 - 1843. [Abstract] [Full Text] [PDF]

				R. C. Drisdel, D. Sharp, T. Henderson, T. G. Hales, and W. N. Green High Affinity Binding of Epibatidine to Serotonin Type 3 Receptors J. Biol. Chem., April 11, 2008; 283(15): 9659 - 9665. [Abstract] [Full Text] [PDF]

				G. Cucchiaro, N. Chaijale, and K. G. Commons The Dorsal Raphe Nucleus as a Site of Action of the Antinociceptive and Behavioral Effects of the {alpha}4 Nicotinic Receptor Agonist Epibatidine J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 389 - 394. [Abstract] [Full Text] [PDF]

				S.-J. Lee, Y. Nakamura, and W. C. de Groat Effect of ({+/-})-epibatidine, a nicotinic agonist, on the central pathways controlling voiding function in the rat Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R84 - R90. [Abstract] [Full Text] [PDF]

				M. Avalos, M. J. Parker, F. N. Maddox, F. I. Carroll, and C. W. Luetje Effects of Pyridine Ring Substitutions on Affinity, Efficacy, and Subtype Selectivity of Neuronal Nicotinic Receptor Agonist Epibatidine J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1246 - 1252. [Abstract] [Full Text] [PDF]

				J. L. Ellis, D. Harman, J. Gonzalez, M. L. Spera, R. Liu, T. Y. Shen, D. M. Wypij, and F. Zuo Development of Muscarinic Analgesics Derived from Epibatidine: Role of the M4 Receptor Subtype J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1143 - 1150. [Abstract] [Full Text]

				P. Curzon, A. L. Nikkel, A. W. Bannon, S. P. Arneric, and M. W. Decker Differences Between the Antinociceptive Effects of the Cholinergic Channel Activators A-85380 and (±)-Epibatidine in Rats J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 847 - 853. [Abstract] [Full Text]

				M. Zoli, C. Lena, M. R. Picciotto, and J.-P. Changeux Identification of Four Classes of Brain Nicotinic Receptors Using beta 2 Mutant Mice J. Neurosci., June 15, 1998; 18(12): 4461 - 4472. [Abstract] [Full Text] [PDF]

				D. L. Donnelly-Roberts, P. S. Puttfarcken, T. A. Kuntzweiler, C. A. Briggs, D. J. Anderson, J. E. Campbell, M. Piattoni-Kaplan, D. G. Mckenna, J. T. Wasicak, M. W. Holladay, et al. ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A Novel, Orally Effective Analgesic Acting via Neuronal Nicotinic Acetylcholine Receptors: I. In Vitro Characterization J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 777 - 786. [Abstract] [Full Text]

				R. J. Prince and S. M. Sine Epibatidine Binds with Unique Site and State Selectivity to Muscle Nicotinic Acetylcholine Receptors J. Biol. Chem., April 3, 1998; 273(14): 7843 - 7849. [Abstract] [Full Text] [PDF]

				M. J. Marks, K. W. Smith, and A. C. Collins Differential Agonist Inhibition Identifies Multiple Epibatidine Binding Sites in Mouse Brain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 377 - 386. [Abstract] [Full Text]

				M. Bencherif, J. D. Schmitt, B. S. Bhatti, P. Crooks, W. S. Caldwell, M. E. Lovette, K. Fowler, L. Reeves, and P. M. Lippiello The Heterocyclic Substituted Pyridine Derivative (±)-2-(-3-pyridinyl)-1-Azabicyclo[2.2.2]octane (RJR-2429): A Selective Ligand at Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 886 - 894. [Abstract] [Full Text]

				J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs, D. J. Anderson, M. Gopalakrishnan, I. C. Xue, M. Piattoni-Kaplan, E. Molinari, J. E. Campbell, D. G. Mckenna, et al. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 235 - 246. [Abstract] [Full Text]